BBBocar Baya

Bocar Baya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bocar Baya has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Schistosoma mansoni co-infection in tuberculosis patients with or without human immunodeficiency virus and factors associated with treatment outcomes: a prospective cohort study

    by Bocar Baya, Bassirou Diarra, Djeneba Koumba Dabitao, Amadou Somboro, Fah Gaoussou Traore, Drissa Goїta, Gagni Coulibaly, Moumine Sanogo, Mamadou Wague, Bourahima Kone, et al.

    Tuberculosis (TB) has resurfaced as the leading cause of death by an infectious agent after the COVID-19 pandemic. The fight against TB needs to consider f


  • Open Access

    Biological diagnosis and characterization of occult hepatitis B virus infection in Burkina Faso

    by Boubacar Doumbia, Birama Diarra, Bourahima Kone, Florencia Djigma, Bocar Baya, Jacque Simpore

    Introduction/objective The occult infection by the hepatitis B virus (OBI) characterized by the undetectable (HBs Ag) negative antigen in the serum and the presence of viral DNA, constitutes a major public health problem and a major challenge for clinical forms of hepatitis worldwide. The persistence of OBI very often leads to hepatocellular carcinoma (HCC) and immunodeficiency. The aim of this study was to estimate the prevalence of OBI and to characterize the incriminated genotypes of the virus. Material and method The plasmas of 252 HBsAg-negative volunteers were used for highlighting the viral DNA by PCR classic. PCR Multiplex using specific primers of 6 genotypes (A to F) was used for characterization. Results A prevalence of 11.9% (30/252) of OBI was obtained with 7.5% in women and 4.4% for men. Genotypes E (60.0%) and A3 (23.3%) were present and genotypes B, C, D, and F were absent. A mixed infection with E/A3 genotypes (16.7%) was observed. AC Anti-HBc was present in 80% of cases OBI. Discussion/Conclusion The prevalence of 11.9% of OBI could be related to the level of endemicity of the study area, Burkina Faso being a country with a prevalence of more than 14% of HBV infection. These infections are dominated by the A3 and E genotypes, confirming their importance in chronic HBV infections. The absence of genotypes B and C in cases of OBI constitutes a positive predictive value since their presence is linked to a more rapid evolution of the infection towards HCC.

  • Sex Differences in Active Pulmonary Tuberculosis Outcomes in Mali, West Africa

    by Djeneba Dabitao, Amadou Somboro, Ibrahim Sanogo, Bassirou Diarra, Chad J. Achenbach, Jane L. Holl, Bocar Baya, Moumine Sanogo, Mamadou Wague, Nadie Coulibaly, et al.

    : Men and women often respond differently to infectious diseases and their treatments. Tuberculosis (TB) is a life-threatening communicable disease that affects more men than women globally. Whether male sex is an independent risk factor for unfavorable TB outcomes, however, has not been rigorously investigated in an African context, where individuals are likely exposed to different microbial and environmental factors. We analyzed data collected from a cohort study in Mali by focusing on newly diagnosed active pulmonary TB individuals who were treatment naive. We gathered baseline demographic, clinical, and microbiologic characteristics before treatment initiation and also at three time points during treatment. More males than females were affected with TB, as evidenced by a male-to-female ratio of 2.4:1. In addition, at baseline, males had a significantly higher bacterial count and shorter time to culture positivity as compared with females. Male sex was associated with lower smear negativity rate after 2 months of treatment also known as the intensive phase of treatment, but not at later time points. There was no relationship between patients’ sex and mortality from any cause during treatment. This study suggests that sex-based differences in TB outcomes exist, with sex-specific effects on disease outcomes being more pronounced before treatment initiation and during the intensive phase of treatment rather than at later phases of treatment.


  • Open Access

    Molecular epidemiology and genetic diversity of Mycobacterium tuberculosis complex in referral health centers of Bamako, Mali: What is new?

    by Bourahima Kone, Anou M. Somboro, Mahamadou Kone, Jane L. Holl, Bocar Baya, Djeneba Dabitao, Dramane Diallo, Bassirou Diarra, Amadou Kone, Yeya Dit Sadio Sarro, et al.


  • Open Access

    High SARS-CoV-2 Seroprevalence among Healthcare Workers in Bamako, Mali

    by Anou M. Somboro, Yacouba Cissoko, Issiaka Camara, Ousmane Kodio, Mohamed Tolofoudie, Etienne Dembele, Antieme C. G. Togo, Djibril M. Ba, Yeya Dit Sadio Sarro, Bocar Baya, et al.

    In Mali, a country in West Africa, cumulative confirmed COVID-19 cases and deaths among healthcare workers (HCWs) remain enigmatically low, despite a series of waves, circulation of SARS-CoV-2 variants, the country’s weak healthcare system, and a general lack of adherence to public health mitigation measures. The goal of the study was to determine whether exposure is important by assessing the seroprevalence of anti-SARS-CoV-2 IgG antibodies in HCWs. The study was conducted between November 2020 and June 2021. HCWs in the major hospitals where COVID-19 cases were being cared for in the capital city, Bamako, Mali, were recruited. During the study period, vaccinations were not yet available. The ELISA of the IgG against the spike protein was optimized and quantitatively measured. A total of 240 HCWs were enrolled in the study, of which seropositivity was observed in 147 cases (61.8%). A continuous increase in the seropositivity was observed, over time, during the study period, from 50% at the beginning to 70% at the end of the study. HCWs who provided direct care to COVID-19 patients and were potentially highly exposed did not have the highest seropositivity rate. Vulnerable HCWs with comorbidities such as obesity, diabetes, and asthma had even higher seropositivity rates at 77.8%, 75.0%, and 66.7%, respectively. Overall, HCWs had high SARS-CoV-2 seroprevalence, likely reflecting a “herd” immunity level, which could be protective at some degrees. These data suggest that the low number of cases and deaths among HCWs in Mali is not due to a lack of occupational exposure to the virus but rather related to other factors that need to be investigated.


  • Short Communication: Genetic Variation in Human IL10 Proximal Promoter and Susceptibility to HIV-1 Infection in Mali, West Africa

    by Djeneba Dabitao, Mamadou Dembele, Michael Urbanowski, Bourahima Kone, Mamadou Wague, Nadie Coulibaly, Yeya Dit Sadio Sarro, Bocar Baya, Drissa Goita, Sounkalo Dao, et al.

    It is now recognized that in order to fully understand the role of host genetic variation on susceptibility to HIV-1 infection, investigations must be extended to African populations. We sought to determine if genetic variation in IL10 are associated with HIV-1 infection in a West African cohort in Mali. HIV-infected and -uninfected individuals were genotyped for three common single nucleotide polymorphisms (SNPs) located at positions -592 (C/A), -819 (C/T), and -1082 (G/A) of the IL10 promoter. We found that the ATA haplotype, which has been previously associated with low IL-10 expression, was the most represented in the cohort. Though we observed a trend towards an increased frequency of ATA/ATA carriage in HIV-infected compared to -uninfected individuals, the difference was not statistically significant. Similarly, individual IL10 SNPs were not significantly enriched in the HIV-infected group, suggesting that IL10 genetic variants are not associated with HIV-1 in this West African cohort from Mali.


  • Open Access

    Association of Mycobacterium africanum Infection with Slower Disease Progression Compared with Mycobacterium tuberculosis in Malian Patients with Tuberculosis

    by Bocar Baya, Bassirou Diarra, Seydou Diabate, Bourahima Kone, Drissa Goita, Yeya Dit Sadio Sarro, Keira Cohen, Jane L. Holl, Chad J. Achenbach, Mohamed Tolofoudie, et al.

    Mycobacterium africanum (MAF) is known to endemically cause up to 40–50% of all pulmonary TB in West Africa. The aim of this study was to compare MAF with Mycobacterium tuberculosis (MTB) with regard to time from symptom onset to TB diagnosis, and clinical and radiological characteristics. A cross-sectional study was conducted in Bamako, Mali, between August 2014 and July 2016. Seventy-seven newly diagnosed pulmonary TB patients who were naive to treatment were enrolled at Mali’s University Clinical Research Center. Sputum cultures were performed to confirm the diagnosis and spoligotyping to identify the mycobacterial strain. Univariate and multivariate analyses were used to identify factors associated with disease progression. Overall, the frequency of female patients was 25% in MAF infection and only 10.0% in MTB infection (OR = 2.9), and MAF was more represented in patients aged ≥ 30 years (57.1% versus 36.7% [OR = 2.3]). More MAF- than MTB-infected patients had a history of a prior TB contact (32.1% versus 14.3% [OR = 2.8]). The mean duration between cough onset and TB diagnosis was 111 days (∼3.7 months) for MAF and 72 days (∼2.4 months) for MTB (P = 0.007). In a multivariate regression, weight loss (body mass index [BMI] < 18.5 kg/m2) and cough duration (> 4 months) were strongly associated with MAF infection (OR = 5.20 [1.49–18.26], P = 0.010, and 4.74 [1.2–18.58], P = 0.02), respectively. Our data show that MAF infection was significantly associated with lower BMI and a longer time between symptom onset and TB diagnosis than MTB. This supports the concept that MAF infection may have slower disease progression and less severe cough symptoms than MTB.


  • Open Access

    Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali

    by Bocar Baya, Chad J. Achenbach, Bourahima Kone, Yacouba Toloba, Djeneba K. Dabitao, Bassirou Diarra, Drissa Goita, Seydou Diabaté, Mamoudou Maiga, Dianguina Soumare, et al.


  • Open Access

    Extensively drug resistant tuberculosis in Mali: a case report

    by Bassirou Diarra, Yacouba Toloba, Bakary Konate, Moumine Sanogo, Antieme Combo Georges Togo, Fatimata Camara, Gaoussou Berthe, Dianguina Soumaré, Bocar Baya, Drissa Goita, et al.

    Drug resistant tuberculosis presents a major public health challenge. We present here the first two patients diagnosed with extensively drug resistant tuberculosis in Bamako, Mali. Genotypic findings suggest possible nosocomial transmission from the first patient to the second one, resulting in superinfection of the second patient. After being diagnosed with extensively drug resistant tuberculosis in August 2016, the patients only started receiving appropriate treatment 10 months later. The identification of these patients highlights the need for improved diagnostic and treatment algorithms for better surveillance and management of drug resistance in Mali. In the interest of these as well as future patients suffering from resistant tuberculosis, all steps recommended for programmatic management of drug resistant tuberculosis must be urgently prioritized in order to strengthen the multidrug resistant tuberculosis program.